Arrowhead Pharmaceuticals, Inc.

Equities

ARWR

US04280A1007

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:03 2024-04-23 pm EDT			5-day change	1st Jan Change
23.78 ^USD	-0.59%		+0.46%	-22.29%

Apr. 07	Arrowhead Pharmaceuticals, Inc. Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo	CI
Mar. 25	Arrowhead Pharmaceuticals, Inc. Initiates Expanded Access Program for Plozasiran	CI

Arrowhead Pharmaceuticals Announces Closing of Agreement with Glaxosmithkline

January 24, 2022 at 07:30 am EST

Arrowhead Pharmaceuticals Inc. announced that the exclusive license agreement between Arrowhead and GlaxoSmithKline announced on November 22, 2021, has now closed. Closing of the transaction was subject to customary closing conditions and expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.

Latest news about Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo	Apr. 07	CI
Arrowhead Pharmaceuticals, Inc. Initiates Expanded Access Program for Plozasiran	Mar. 25	CI
Arrowhead Doses First Subjects in Phase 1/2a Study of Myotonic Dystrophy Treatment; Shares Rise	Mar. 08	MT
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy	Mar. 08	CI
Certain Restricted Stock Units of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 3-MAR-2024.	Mar. 02	CI
Certain Common Stock of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 3-MAR-2024.	Mar. 02	CI
Arrowhead Pharmaceuticals, Inc. Appoints Hongbo Lu as Independent Director, Effective April 1, 2024	Feb. 22	CI
B. Riley Adjusts Arrowhead Pharmaceuticals' PT to $55 From $50, Keeps Buy Rating	Feb. 08	MT
Sector Update: Health Care Stocks Firmer Late Afternoon	Feb. 07	MT
Sector Update: Health Care Stocks Advance in Afternoon Trading	Feb. 07	MT
UBS Adjusts Price Target on Arrowhead Pharmaceuticals to $75 From $78, Maintains Buy Rating	Feb. 07	MT
Sector Update: Health Care Stocks Mixed Premarket Wednesday	Feb. 07	MT
Arrowhead Pharmaceuticals Fiscal Q1 Loss Widens, Revenue Declines	Feb. 07	MT
Transcript : Arrowhead Pharmaceuticals, Inc., Q1 2024 Earnings Call, Feb 06, 2024	Feb. 06
Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 06	CI
Arrowhead Pharmaceuticals Insider Sold Shares Worth $1,860,019, According to a Recent SEC Filing	Feb. 02	MT
Arrowhead Pharmaceuticals, Inc. Announces Leaving of Javier San Martin, M.D., as the Chief Medical Officer, Effective from February 1, 2024	Jan. 22	CI
Arrowhead Pharmaceuticals Insider Sold Shares Worth $292,804, According to a Recent SEC Filing	Jan. 08	MT
Arrowhead Pharmaceuticals Insider Sold Shares Worth $567,910, According to a Recent SEC Filing	Jan. 08	MT
Transcript : Arrowhead Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 08:15 AM	Jan. 08
Arrowhead Pharmaceuticals Shares Rise as $450 Million Underwritten Share Offering Priced	Jan. 03	MT
Arrowhead Pharmaceuticals Prices $450 Million Underwritten Share Offering	Jan. 03	MT
Arrowhead Pharmaceuticals Insider Sold Shares Worth $342,480, According to a Recent SEC Filing	Dec. 22	MT
North American Morning Briefing : China Outlook -2-	Dec. 05	DJ
BofA Securities Initiates Arrowhead Pharmaceuticals at Buy Rating With $29 Price Target	Dec. 04	MT

Chart Arrowhead Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Arrowhead Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

23.78 USD

Average target price

55.15 USD

Spread / Average Target

+131.93%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ARROWHEAD PHARMACEUTICALS, INC.	-22.29%	2.95B
VERTEX PHARMACEUTICALS INCORPORATED	-0.49%	105B
REGENERON PHARMACEUTICALS, INC.	+3.31%	97.5B
ARGENX SE	+2.97%	22.19B
BIONTECH SE	-16.16%	21.33B
GENMAB A/S	-7.35%	18.68B
WUXI APPTEC CO., LTD.	-41.41%	16.6B
BEIGENE, LTD.	-22.87%	14.52B
NEUROCRINE BIOSCIENCES, INC.	+6.32%	14.09B
SAREPTA THERAPEUTICS, INC.	+21.46%	10.99B

Bio Therapeutic Drugs